Titre :

Stabilization of Human Tyrosine Hydroxylase in Maltodextrin Nanoparticles for Delivery to Neuronal Cells and Tissue

Auteur(s) :

Bezem, Maria T. [Auteur]
Johannessen, Fredrik G. [Auteur]
Jung Kunwar, K. C. [Auteur]
Gundersen, Edvin Tang [Auteur]
Jorge-Finnigan, Ana [Auteur]
Ying, Ming [Auteur]
Betbeder, Didier [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Herfindal, Lars [Auteur]
Martinez, Aurora [Auteur]

Titre de la revue :

Bioconjugate chemistry

Nom court de la revue :

Bioconjugate Chem.

Numéro :

29

Pagination :

493-502

Date de publication :

2018-02-01

ISSN :

1043-1802

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Enzyme replacement therapy (ERT) is a therapeutic approach envisioned decades ago for the correction of genetic disorders, but ERT has been less successful for the correction of disorders with neurological manifestations. ...
Lire la suite >Enzyme replacement therapy (ERT) is a therapeutic approach envisioned decades ago for the correction of genetic disorders, but ERT has been less successful for the correction of disorders with neurological manifestations. In this work, we have tested the functionality of nanoparticles (NP) composed of maltodextrin with a lipid core to bind and stabilize tyrosine hydroxylase (TH). This is a complex and unstable brain enzyme that catalyzes the rate-limiting step in the synthesis of dopamine and other catecholamine neurotransmitters. We have characterized these TH-loaded NPs to evaluate their potential for ERT in diseases associated with TH dysfunction. Our results show that TH can be loaded into the lipid core maltodextrin NPs with high efficiency, and both stability and activity are maintained through loading and are preserved during storage. Binding to NPs also favored the uptake of TH to neuronal cells, both in cell culture and in the brain. The internalized NP-bound TH was active as we measured an increase in intracellular L-Dopa synthesis following NP uptake. Our approach seems promising for the use of catalytically active NPs in ERT to treat neurodegenerative and neuropsychiatric disorders characterized by dopamine deficiency, notably Parkinson's disease.Lire moins >

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Équipe(s) de recherche :

Therapeutic innovation targetting inflammation

Date de dépôt :

2019-05-17T13:08:37Z